5 amino 1mq pharmacogenetics snp rsid 5-Amino-1MQ (5mg & 50mg) for Research 5-Amino-1MQ | peptide+
Description
The FDA recently banned AOD 9604 from compounding due to safety concerns and lack of approval for medical use
The most comprehensive study, published in BioMed Research International (2021), found that 5-amino-1MQ treatment "reverses diet-induced obesity and related T2D" in obese mice
Researchers often investigate 5-Amino-1MQ in combination with precursors like Nicotinamide Riboside (NR) or NMN
While cyanocobalamin can still raise blood levels, it may not act as quickly or effectively in neurological tissue
